Volume 34, Issue 2 (March & April 2026)
J Adv Med Biomed Res 2026, 34(2): 142-145 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Gholami N, Aghaei S, Ravaei G. Central Diabetes Insipidus in a Patient with Acute Myeloid Leukemia: A Case Report. J Adv Med Biomed Res 2026; 34 (2) :142-145
URL: http://journal.zums.ac.ir/article-1-7703-en.html
URL: http://journal.zums.ac.ir/article-1-7703-en.html
1- Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2- Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran ,shalalehaghaei@gmail.com
2- Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran ,
Abstract: (381 Views)
| Central diabetes insipidus (CDI) is an uncommon but potentially life-threatening complication in patients with hematologic malignancies. We report the case of a 30-year-old man who presented with upper respiratory symptoms, followed by progressive fatigue, polydipsia, and polyuria. Laboratory evaluation revealed pancytopenia, and bone marrow biopsy confirmed the diagnosis of AML-M2. Despite initial chemotherapy, the patient experienced persistent polyuria and hypernatremia (148–156 mmol/L). Endocrine evaluation revealed a urine osmolality of 159 mOsm/kg, a serum osmolality of 298 mOsm/kg, and a desmopressin challenge confirmed CDI (>50% increase in urine osmolality). MRI demonstrated the loss of the posterior pituitary hyperintensity and deviation of the pituitary stalk. The patient was treated with intranasal desmopressin, resulting in symptomatic improvement. Despite therapy, the leukemia proved refractory, and the patient eventually succumbed to disease progression. This case underscores the importance of early recognition of CDI in patients with AML, as timely diagnosis and management can mitigate severe complications. |
Type of Study: Case Report Article |
Subject:
Clinical Medicine
Received: 2025/10/7 | Accepted: 2026/03/17 | Published: 2026/05/20
Received: 2025/10/7 | Accepted: 2026/03/17 | Published: 2026/05/20
References
1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200-28. [DOI:10.1182/blood.2022015850] [PMID] [PMCID]
2. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-77. [DOI:10.1182/blood.2022016867] [PMID]
3. Cull E, Watts J, Tallman M, Kopp P, Frattini M, Rapaport F, et al. Acute myeloid leukemia presenting with panhypopituitarism or diabetes insipidus: A case series with molecular genetic analysis and review of the literature. Leukem Lymph. 2013;55. [DOI:10.3109/10428194.2013.869327] [PMID]
4. Harb A, Tan W, Wilding GE, Battiwalla M, Sait SN, Wang ES, et al. Acute myeloid leukemia and diabetes insipidus with monosomy 7. Cancer Genet Cytogenet. 2009;190(2):97-100. [DOI:10.1016/j.cancergencyto.2009.01.006] [PMID]
5. Makaryus AN, McFarlane SI. Diabetes insipidus: diagnosis and treatment of a complex disease. Cleveland Clin J Med. 2006;73(1):65-71. [DOI:10.3949/ccjm.73.1.65] [PMID]
6. Chuang C, Parnerkar V, Radulescu A, Hunt MA, Cayci Z, Ustun C. Diabetes insipidus in myelodysplastic syndrome: what we learnt from a case regarding its diagnosis, pathophysiology and management. Leukem Lymph. 2015;56(4):1134-6. [DOI:10.3109/10428194.2014.946029] [PMID]
7. Nakamura F, Kishimoto Y, Handa T, Arai Y, Mitani K. Myelodysplastic syndrome with central diabetes insipidus manifesting hypodipsic hypernatremia and dehydration. Am J Hematol. 2004;75(4):213-6. [DOI:10.1002/ajh.20017] [PMID]
8. Ladigan S, Mika T, Figge A, May AM, Schmiegel W, Schroers R, et al. Acute myeloid leukemia with central diabetes insipidus. Blood Cells Mol Dis. 2019;76:45-52. [DOI:10.1016/j.bcmd.2019.01.005] [PMID]
9. Wössmann W, Borkhardt A, Gossen R, Göbel FJ, Reiter A. Acute myeloid leukemia presenting with diabetes insipidus. Europ J Pediatr. 2002;161(3):161-2. [DOI:10.1007/s00431-001-0897-1] [PMID]
10. Keung YK, Buss D, Powell BL, Pettenati M. Central diabetes insipidus and inv(3)(q21q26) and monosomy 7 in acute myeloid leukemia. Cancer Genet Cytogenet. 2002;136(1):78-81. [DOI:10.1016/S0165-4608(02)00521-6] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |